JPWO2019204583A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019204583A5 JPWO2019204583A5 JP2020556835A JP2020556835A JPWO2019204583A5 JP WO2019204583 A5 JPWO2019204583 A5 JP WO2019204583A5 JP 2020556835 A JP2020556835 A JP 2020556835A JP 2020556835 A JP2020556835 A JP 2020556835A JP WO2019204583 A5 JPWO2019204583 A5 JP WO2019204583A5
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- inhalable dry
- itraconazole
- powder according
- inhalable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims 33
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 13
- 229960004130 itraconazole Drugs 0.000 claims 13
- 239000012669 liquid formulation Substances 0.000 claims 12
- 239000002245 particle Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 7
- 229920000053 polysorbate 80 Polymers 0.000 claims 7
- 229940068968 polysorbate 80 Drugs 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000003380 propellant Substances 0.000 claims 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 3
- 235000011152 sodium sulphate Nutrition 0.000 claims 3
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 2
- -1 cation salt Chemical class 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 230000009798 acute exacerbation Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659479P | 2018-04-18 | 2018-04-18 | |
| US62/659,479 | 2018-04-18 | ||
| PCT/US2019/028089 WO2019204583A1 (en) | 2018-04-18 | 2019-04-18 | Antifungal formulations for pulmonary administration comprising itraconazole |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522161A JP2021522161A (ja) | 2021-08-30 |
| JPWO2019204583A5 true JPWO2019204583A5 (ko) | 2022-04-14 |
| JP7549534B2 JP7549534B2 (ja) | 2024-09-11 |
Family
ID=66429608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556835A Active JP7549534B2 (ja) | 2018-04-18 | 2019-04-18 | イトラコナゾールを含む肺内投与のための抗真菌配合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210145739A1 (ko) |
| EP (1) | EP3781125A1 (ko) |
| JP (1) | JP7549534B2 (ko) |
| WO (1) | WO2019204583A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000030443A1 (it) * | 2020-12-10 | 2022-06-10 | Zambon Spa | Polvere inalabile comprendente voriconazolo in forma cristallina |
| IT202000030437A1 (it) * | 2020-12-10 | 2022-06-10 | Zambon Spa | Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo |
| US11471475B1 (en) | 2022-03-08 | 2022-10-18 | Ralph P. Stone | Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery |
| WO2024040175A1 (en) | 2022-08-18 | 2024-02-22 | Pulmatrix Operating Company, Inc. | Methods for treating cancer using inhaled angiogenesis inhibitor |
| WO2024049982A2 (en) | 2022-08-31 | 2024-03-07 | Pulmatrix Operating Company, Inc. | Methods of using itraconazole dry powders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US4916134A (en) | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| AU2002245181B2 (en) * | 2000-12-21 | 2006-06-29 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| US9061027B2 (en) * | 2004-08-27 | 2015-06-23 | Board Of Regents, The University Of Texas System | Enhanced delivery of drug compositions to treat life threatening infections |
| US20110142914A1 (en) * | 2007-12-06 | 2011-06-16 | Cytotech Labs, Llc | Inhalable compositions having enhanced bioavailability |
| EP2095816A1 (en) | 2008-02-29 | 2009-09-02 | Schlichthaar, Rainer, Dr. | Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| CN103228266B (zh) * | 2010-10-29 | 2017-11-14 | 健康科学西部大学 | 三元混合物制剂 |
| CA2865972C (en) * | 2012-02-29 | 2022-01-04 | Pulmatrix, Inc. | Inhalable dry powders |
| EP3525759A1 (en) | 2016-10-14 | 2019-08-21 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
-
2019
- 2019-04-18 US US17/048,491 patent/US20210145739A1/en active Pending
- 2019-04-18 JP JP2020556835A patent/JP7549534B2/ja active Active
- 2019-04-18 EP EP19722383.7A patent/EP3781125A1/en active Pending
- 2019-04-18 WO PCT/US2019/028089 patent/WO2019204583A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534270A5 (ko) | ||
| Lin et al. | Powder production and particle engineering for dry powder inhaler formulations | |
| RU2013118453A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| RU2766086C2 (ru) | Противогрибковые сухие порошки | |
| CN103841960B (zh) | 用于吸入的方法和制剂 | |
| JP2013540123A5 (ko) | ||
| JP2023086774A (ja) | 乾燥粉末配合および使用方法 | |
| JP7048642B2 (ja) | 肺、鼻、舌下および／または咽頭への送達に適した、少なくとも１つの生物活性化合物をロードした多孔質シリカ粒子の製造方法 | |
| JP2016519160A (ja) | ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム | |
| JP7549534B2 (ja) | イトラコナゾールを含む肺内投与のための抗真菌配合物 | |
| JP2020536123A5 (ko) | ||
| US20190167579A1 (en) | Itraconazole dry powders | |
| JP6850524B2 (ja) | 吸入用の乾燥粉末製剤 | |
| JPWO2019204583A5 (ko) | ||
| AU2019256453B2 (en) | Methods of treating fungal infections | |
| JP2023521396A (ja) | ペラミビル乾燥粉末吸入剤及びその調製方法 | |
| WO2022122012A1 (zh) | 用于肺部递送的药物组合物 | |
| JP2024501372A (ja) | 吸入用医薬組成物 | |
| RU2820457C2 (ru) | Способы лечения грибковых инфекций | |
| JPWO2020074894A5 (ko) | ||
| Dongare et al. | An Overview of Recently Published Patents on Pulmonary Drug Delivery Devices | |
| KR102259824B1 (ko) | 보센탄을 함유한 약학 제제 | |
| Moon et al. | and Robert O. Williams III1 | |
| Moon et al. | Thin-Film Freeze-Drying Process for Versatile Particles for Inhalation Drug Delivery | |
| CA3060020A1 (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |